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Abstract
The class IB phosphoinositide 3-kinase gamma enzyme complex (PI3Kc) functions in multiple signaling pathways involved
in leukocyte activation and migration, making it an attractive target in complex human inflammatory diseases including MS.
Here, using pik3cg2/2 mice and a selective PI3Kc inhibitor, we show that PI3Kc promotes development of experimental
autoimmune encephalomyelitis (EAE). In pik3cg2/2 mice, EAE is markedly suppressed and fewer leukocytes including CD4+
and CD8+ T cells, granulocytes and mononuclear phagocytes infiltrate the CNS. CD4+ T cell priming in secondary lymphoid
organs is reduced in pik3cg2/2 mice following immunisation. This is attributable to defects in DC migration concomitant
with a failure of full T cell activation following TCR ligation in the absence of p110c. Together, this results in suppressed
autoreactive T cell responses in pik3cg2/2 mice, with more CD4+ T cells undergoing apoptosis and fewer cytokine-
producing Th1 and Th17 cells in lymphoid organs and the CNS. When administered from onset of EAE, the orally active
PI3Kc inhibitor AS605240 caused inhibition and reversal of clinical disease, and demyelination and cellular pathology in the
CNS was reduced. These results strongly suggest that inhibitors of PI3Kc may be useful therapeutics for MS.
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Introduction
Multiple Sclerosis (MS) is the most common inflammatory
disorder of the central nervous system (CNS) and is a chronic,
debilitating and demyelinating disease. Following breakdown of
immunological tolerance to CNS antigens by unknown mechan-
ism(s), T and B cells invade the CNS initiating the accumulation of
innate immune effector cells within the brain and spinal cord. The
resulting inflammation leads to CNS demyelination, oligodendro-
cyte loss, axonal degeneration and impaired nervous system
function [1]. Autoimmune responses similar to those in MS are
commonly modelled using experimental autoimmune encephalo-
myelitis (EAE) in mice, which allows experimental dissection of the
molecular mechanisms driving CNS autoimmunity [2]. In active
EAE, autoreactive encephalitogenic Th1 and Th17 CD4+ T cells
are activated through immunisation, invade the CNS and
subsequently promote the recruitment of immune effector cells
such as monocytes and neutrophils, resulting in demyelinating
autoimmune inflammation that resembles human MS in many
clinical and histopathological features. This model is commonly
used to assess the importance of molecular and cellular
components in CNS autoimmunity and provide proof-of-concept
for novel therapeutics for human MS [2,3]. For example,
sphingosine-1 phosphate receptor agonists and antibody-mediated
blockade of the a4-integrin were shown to be effective inhibitors of
EAE [4,5], subsequently leading to the development of Fingolimod
and Natiluzimab respectively, as current MS therapeutics used in
the clinic. However, while these therapies are proving of some
benefit in treating MS, more effective therapies are required which
necessitates identification and evaluation of novel therapeutic
targets.
Phosphoinositide-3-kinases (PI3Ks) are a large family of dual-
specificity lipid and protein kinases known mainly for their role in
catalysing the phosphorylation of phosphatidylinositol-4,5-bipho-
sphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3),
a key second messenger that recruits PH-domain containing
proteins, such as Akt, to the plasma membrane to initiate signal
transduction cascades important for cell proliferation, migration
and survival [6]. Class IA PI3Ks are generally activated
downstream of receptor tyrosine kinases (RTKs) whilst the class
IB PI3K (PI3Kc) is activated by G-Protein coupled receptor
(GPCR) triggering. Our previous work identified a role for the
class IA PI3K, PI3Kd, in promoting Th17 responses during EAE
[7]. Unlike the two other class I isoforms of PI3K that are essential
for life (PI3Ka and PI3Kb) [8,9], PI3Kd and PI3Kc are not
essential for development and display a restricted pattern of
expression, mainly confined to cells of the immune system where
they contribute to the control of leukocyte activation and
migration [10,11,12,13]. Consisting of a catalytic p110c subunit
and two regulatory subunits (p101 and p84), PI3Kc has been
shown to play an important role in promoting migration and
activation of various leukocyte subsets including neutrophils,
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mononuclear phagocytes and some lymphocytes following activa-
tion downstream of GPCRs, such as chemokine receptors
[13,14,15,16]. Thus, PI3Kc has been shown to make an important
contribution to the pathogenesis of several animal models of
human inflammatory diseases including rheumatoid arthritis (RA),
asthma, systemic lupus erythematosus (SLE) and diabetes
[17,18,19,20,21,22] and is under investigation as a drug target
for a variety of human inflammatory disorders [23]. Therefore, it
is likely that PI3Kc inhibition has the potential to attenuate MS.
Here we have used pik3cg2/2 mice, which lack expression of
p110c, and a highly selective PI3Kc inhibitor to conduct a detailed
investigation of the role of this protein in CNS autoimmune
disease and we show that PI3Kc plays a critical role in EAE by
controlling CD4+ T cell activation and survival.
Results
Lack of p110c Prevents Development of EAE
To investigate the role of PI3Kc in CNS autoimmune disease,
EAE was induced in WT and pik3cg2/2 mice, which lack the
catalytic subunit of PI3Kc, p110c. A profound inhibition of
clinical disease was apparent in pik3cg2/2 mice (Figure 1A and B).
Remarkably, while the incidence of disease in WT mice was
100%, greater than 75% of the pik3cg2/2 mice immunized for
EAE remained completely free of clinical disease signs within the 4
weeks following disease induction and, in those that developed
EAE, clinical signs were mild and onset was substantially delayed
compared with WT mice (Table 1). Histological analyses of spinal
cord tissue taken on day 15 post-immunisation when peak disease
was apparent in WT mice revealed that pik3cg2/2 mice lacked the
characteristic lesions containing infiltrating leukocytes, while these
were clearly apparent in WT spinal cord sections (Figure 1C).
Furthermore, luxol fast blue staining of spinal cord from mice
immunized for EAE revealed no evidence of CNS demyelination
in pik3cg2/2 mice whilst this was an obvious feature in WT spinal
cord sections (Figure 1D). These data clearly indicate that p110c
plays a key role in driving demyelinating autoimmunity in the
CNS.
Reduced Immune Priming of CD4+ T Cells during EAE in
the Absence of p110c
EAE is a CD4+ T cell-driven autoimmune disease [24].
Therefore the nature and magnitude of CD4+ T cell responses
occurring in secondary lymphoid organs of pik3cg2/2 and WT
mice was compared. While no differences in CD4+ T cell
frequencies in secondary lymphoid organs of WT or pik3cg2/2
mice at resting state were detected (data not shown), clear defects
in T cell priming following EAE immunization were apparent in
pik3cg2/2 mice. Surface expression of the early activation marker
CD69 on CD4+ T cells following immunization was reduced by
approximately 50% in the absence of p110c (Figure 2A) and this
corresponded with a notable reduction in CD4+ T cell pro-
liferation in both LN and spleen following immunization in
pik3cg2/2 relative to WT mice (Figure 2B). Expression of
additional CD4+ T cell activation markers CD44 and CD86 was
also reduced in pik3cg2/2 mice compared with WT (data not
shown). Furthermore, chemokine receptors expression by CD4+ T
cells was also examined following EAE immunization and pik3cg2/
2 mice displayed higher frequencies of CD4+ T cells positive for
the homeostatic chemokine receptor CCR7 than WT mice and
lower frequencies positive for the inflammatory chemokine
receptors CCR6 and CXCR3 (Figure 2C). In addition, expression
of the adhesion molecules CD62L, PSGL-1 and VLA-4 on CD4+
T cells also differed between WT and pik3cg2/2 mice following
immunization for EAE. Specifically, we measured a trend for the
LN-homing selectin CD62L to be present on a higher proportion
of CD4+ T cells from pik3cg2/2 mice than WT (although this did
not reach statistical significance), while the selectin PSGL-1 and
integrin CD49b (VLA-4) were expressed on lower proportions of
CD4+ T cells in pik3cg2/2 mice than WT (Figure 2D), indicative of
reduced CD4+ T cell activation in these mice. Furthermore, we
also measured markedly reduced frequencies of memory (CD44hi/
CD45RO+) CD4+ T cells in pik3cg2/2 mice relative to WT 28
days after immunization for EAE (data not shown). Clear
deficiencies in cytokine production by pik3cg2/2 CD4+ T cells
were also apparent. Frequencies of IFNc-producing Th1 and IL-
17A-producing Th17 cells in both LN and spleen were reduced by
2 to 5-fold in pik3cg2/2 mice compared with WT following
immunization for EAE (Figure 3A). Also notable was an almost
complete lack of highly pathogenic CD4+ T cells that express both
IFNc and IL-17A in pik3cg2/2 lymphoid organs, whilst these were
present in WT (Figure 3A). A marked reduction in Tc1 and Tc17
cells was also measured in the CD8+ T cell compartment of
pik3cg2/2 mice compared with WT following immunization for
EAE (Figure 3B). Collectively, these data demonstrate that T cell
priming during EAE is profoundly diminished in the absence of
PI3Kc signals and that pik3cg2/2 CD4+ T cells do not acquire the
surface phenotype, trafficking capability or the proliferative
capacity of encephalitogenic WT CD4+ T cells and do not
produce cytokines that contribute to EAE pathogenesis.
p110c is Required for Optimal Dendritic Cell Migration
and T Cell Activation
The evident defects in CD4+ T cell priming apparent pik3cg2/2
secondary lymphoid tissues may be explained by two, not
necessarily mutually exclusive, mechanisms: a failure of antigen-
presenting cell (APC) function and/or an intrinsic defect in T cell
activation. A role for PI3Kc has been implicated in both of these
processes by other investigators [13,14,25]. Therefore, these
possibilities were examined in the context of the EAE model.
Time-course analysis of DC trafficking to the draining LN (DLN)
following subcutaneous immunisation for EAE revealed that in
pik3cg2/2 mice, CD11c+/MHC class IIhi DCs were less abundant
than in WT mice 48 hours following immunization (Figure 4A),
although normal frequencies of DCs have been reported to reside
in the skin of these mice [14]. This suggests that p110c is required
for optimal DC migration to secondary lymphoid organs during
EAE. Next, we tested CD4+ T cell functionality in these mice. In
vitro activation of T cells via anti-CD3 crosslinking revealed that
pik3cg2/2 CD4+ T cells had a reduced capacity to proliferate
(Figure 4B) and produce IFNc than WT CD4+ T cells (Figure 4C),
indicating an intrinsic role for p110c in TCR signaling. Together
these data indicate that PI3Kc signaling is required for triggering
of the immune system through at least two separate mechanisms:
by promoting efficient DC trafficking and by promoting T cell
activation, in terms of proliferation and cytokine production.
CNS Infiltration of Pathogenic Leukocyte Populations is
Reduced and CD4+ T Cell Apoptosis Increased in
pik3cg2/2 Mice
Next, the consequence of these defects on infiltration of the
CNS by immune effector cells following EAE induction in WT
and pik3cg2/2 mice were investigated. Flow cytometric analysis
revealed profoundly reduced frequencies of CD4+ and CD8+ T
cells, B cells, macrophages and neutrophils in the spinal cord of
pik3cg2/2 mice compared with WT (Figure 5A). Furthermore,
CD4+ cells could clearly be detected within perivascular cuffs
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and the parenchyma of WT spinal cord, but were not
detectable in pik3cg2/2 mice (Figure 5B). Th17 and Th1 cells
that invade the CNS have a major role in initiating and
maintaining disease pathogenesis [26]. When frequencies of
these cells in the CNS was examined after EAE induction, clear
reductions in Th1 cells were apparent in pik3cg2/2 mice at both
day 9 and day 15 post-immunisation. Th17 cells were not
detectable on day 9 post-immunisation in pik3cg2/2 spinal cords
but were present at equivalent frequencies on day 15 post-
immunisation (Figure 5C). We hypothesized that these evident
reductions in cytokine-producing CD4+ T cells present in the
CNS of EAE-immunised pik3cg2/2 mice were, at least in part,
caused by increased T cell apoptosis resulting from the lack of
PI3Kc signaling. To address this, apoptotic CD4+ T cells in the
CNS of mice immunized for EAE on day 9 and day 15 were
enumerated by flow cytometry. At both time-points, significantly
increased proportions of CD4+ T cells were apoptotic in spinal
cords of pik3cg2/2 compared to WT mice (Figure 6A). This
increase in apoptosis was specific to the CD4+ compartment as
CD45R+ and CD8+ cells had equivalent frequencies of
apoptotic cells between pik3cg2/2 and WT (data not shown).
Furthermore, results from in vitro polyclonal T cell activation
following CD3 cross-linking indicated that CD4+ T cells from
pik3cg2/2 mice died more rapidly of apoptosis than those from
WT mice (Figure 6B). Together, these studies using GM mice
lacking PI3Kc signaling strongly suggest that this enzyme plays
a critical role in CNS autoimmunity by promoting autoreactive
T cell responses.
Figure 1. EAE is suppressed in pik3cg2/2 mice. (A) EAE was induced in pik3cg2/2 (n = 21) and WT (n = 19) mice. Clinical disease scores are
plotted as mean 6 s.e.m. from each mouse. Data is pooled from 3 independent experiments. (B) Clinical disease scores expressed as cumulative
disease scores over time. (C) Histology of spinal cords from pik3cg2/2 and WT mice at day 15 post-immunization for EAE. As indicated, sections were
stained with haematoxylin and eosin (H+E), luxol fast blue, haematoxylin and eosin (LFB/H+E). Images are representative of those taken from multiple
sections. Arrows indicate lesions or demyelinated areas.
doi:10.1371/journal.pone.0045095.g001
Table 1. Effect of deletion of p110c on EAE.
Genotype Incidence Lethality Day of Onset Maximum Disease Score
Mean Cumulative Disease
Score
WT 100% (19/19) 0% (0/19) 11.5 (60.55) 2.33 (60.24) 26.1 (614.8)
pik3cg2/2 23.8% (5/21)*** 0% (0/21) 26.4 (60.05)*** 0.31 (60.17)*** 0.85 (62.0)***
Data are shown as mean 6 s.d. Day of disease onset is the day an animal first displayed clinical signs of EAE. Maximum disease score is the highest clinical disease score
recorded. Mean cumulative disease score is the accumulated total disease score obtained by mice taken to day 28 post-immunisation. Data is pooled from 3
independent experiments.
doi:10.1371/journal.pone.0045095.t001
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Figure 2. Priming of pik3cg2/2 CD4+ T cells is reduced during EAE. (A) Frequencies of CD4+ cells in draining LN that are CD69+ on day 9 post-
immunisation for EAE as determined by flow cytometry. A representative histogram overlay gating on CD4+ cells is shown (filled = isotype control on
WT, solid line = anti-CD69 on WT, dotted line = anti-CD69 on pik3cg2/2) (B) In vivo proliferation of CD4+ cells, measured by BrdU incorporation, is
reduced in pik3cg2/2 mice at day 9 post-immunization for EAE. (n = 6 mice per group). Representative dot plots gating on CD4+ cells are shown. (C)
Expression of chemokine receptors by CD4+ T cells indicative of T cell activation was determined by flow cytometry. Representative histogram
overlays showing expression of CCR7, CCR6 and CXCR3 are shown (filled = isotype control, solid line =WT, dotted line = pik3cg2/2). (D) Expression of
CD62L, CD49d and PSGL-1 by CD4+ cells from spleen of day 9 immunised mice (n = 3 mice per group). All data shown are mean 6 s.e.m. (*, p,0.05).
doi:10.1371/journal.pone.0045095.g002
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Oral Administration of a PI3Kc Inhibitor Prevents
Development of EAE
To address whether PI3Kc is a good candidate drug target for
CNS autoimmunity, the efficacy of an orally active PI3Kc
inhibitor at treating EAE was assessed. Mice were immunized
for EAE and on the day of clinical disease onset were treated with
30 mg/kg of AS605240 (a highly selective PI3Kc inhibitor)
[18,19], or vehicle control, by oral gavage. Remarkably, 60% of
the AS605240-treated mice fully recovered from EAE and
displayed no more clinical signs during the course of the treatment
(Table 2). All vehicle-only treated mice continued to succumb to
clinical EAE. Significantly reduced clinical disease scores and
cumulative disease scores were apparent in AS605240-treated
mice (Figure 7A and Table 2). Histological analysis of the CNS of
these mice at the end of the treatment period revealed that the
AS605240-treated group had reduced cellular pathology in the
spinal cord and reduced signs of demyelination compared with the
control group (Figure 7B).
Discussion
In this manuscript we demonstrate that PI3Kc signalling plays
a major role in the development of EAE and provide evidence
supporting the notion that PI3Kc inhibitors may be useful
therapeutics in demyelinating human autoimmune diseases such
as MS. Mice lacking PI3Kc signalling capacity are markedly
protected from the clinical signs of EAE and have reduced
histopathological signs of demyelinating CNS autoimmunity. This
is likely due, at least in part, to the combined effect of multiple
defects that were measured in the activation of the immune system
when PI3Kc signalling is absent, including reduced DC migration,
reduced TCR-induced activation of CD4+ T cells and enhanced
CD4+ T cell apoptosis. The efficacy of an orally active PI3Kc
inhibitor in a therapeutic setting was also tested, revealing that
PI3Kc inhibition prevents further development of EAE after the
onset of clinical symptoms and reverses clinical disease.
The mechanism of inhibition of EAE when PI3Kc is deleted or
inhibited is likely to be due to combined disruptions to leukocyte
migration, activation and survival. A role for PI3Kc in DC
trafficking from skin to the DLN has been previously reported [14]
and our results are consistent with this defect in pik3cg2/2 mice
influencing the outcome of EAE immunisation. As peripheral
presentation of CNS auto-antigen is also a feature of MS [27], this
may have implications for targeting PI3Kc in MS. However, this
DC migratory defect was only partial and is unlikely to completely
account for the substantial decrease in clinical EAE measured here
Figure 3. Reduced priming of cytokine-producing CD4 and CD8 T cells during EAE in pik3cg2/2mice. (A) The proportion of Th1 (IFN-c+/
IL-172/CD4+ cells) and Th17 (Th17 (IFN-c2/IL-17+/CD4+ cells) cells in the draining LNs and spleen was assessed by isolating lymphocytes at days 9 and
15 post-immunization for EAE and staining for surface CD4 and intracellular cytokines. Representative flow cytometric dot plots of LN and spleen
CD4+ cells are shown. (B) The proportion of Tc1 (IFN-c+/IL-172/CD8+ cells) and Tc17 (IFN-c2/IL-17+/CD8+ cells) cells in the draining LNs and spleen was
assessed by isolating lymphocytes at days 9 and 15 post-immunization for EAE and staining for surface CD8 and intracellular cytokines.
Representative flow cytometric dot plots of LN and spleen CD8+ cells are shown. All data shown are mean 6 s.e.m. n = 6 mice per group. (*, p,0.05).
doi:10.1371/journal.pone.0045095.g003
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in pik3cg2/2 mice. The possibility that additional defects in
leukocyte migration, particularly the migration of antigen-specific
T cells to the CNS, contribute to the effect of deleting or inhibiting
PI3Kc during EAE is likely, however this was not fully addressed
in the present study because following immunisation, pik3cg2/2
CD4+ T cells expressed reduced levels of inflammatory chemokine
receptors, and were inadequately primed, making execution and
interpretation of adoptive transfer EAE experiments using T cells
from pik3cg2/2 mice problematic. The reduced CXCR3 measured
on CD4+ T cells during EAE in pik3cg2/2 mice is in line with
a recent study by Barbi et al., who demonstrated that induction of
CXCR3 expression on T cells is PI3Kc-dependent [28], although
the reduced priming of CD4+ T cells measured in the present
study may also contribute to our observation. Our data therefore
also suggest that expression of CCR6 on CD4+ T cells may have
a PI3Kc-dependent component although this was not tested
directly in the present study. Nevertheless, a defect in leukocyte
migration contributing to the reduced pathology of EAE in
pik3cg2/2 mice is highly likely and supported by our observations
of reduced in vitro migration of pik3cg2/2 compared with WT
lymphocytes to both homeostatic (CCL19 and CXCL12) and
inflammatory (CXCL11 and CCL20) chemokines (data not
shown). We, and others, have shown that the CCR6/CCL20 axis
is involved in the pathogenesis of EAE [29,30,31], and that
blockade of CXCR3 inhibits entry of encephalitogenic CD4+ T
cells into the CNS [32,33]. PI3Kc has been shown to be essential
for chemokine-driven migration and adhesion of neutrophils
[10,13,16,34], monocytes/macrophages [10,15,35] and eosino-
phils [36], although its essential contribution to lymphocyte
migration appears to be highly cell type- and chemoattractant
receptor-specific. While B cell migration appears to be largely
PI3Kc independent, with PI3Kd the major contributor [37], T
Figure 4. Dendritic cell migration and in vitro T cell activation are reduced in the absence of PI3Kc signaling. (A) DLNs from WT and
pik3cg2/2 mice were harvested either prior to, or 2 or 5 days-post immunisation for EAE, collagenase treated and CD11c+/MHCclassIIhi cells
enumerated by flow cytometry. Representative dot plots gating on migratory DCs are shown. (B) Proliferation of pik3cg2/2 CD4+ cells in vitro is
inhibited following TCR stimulation. Splenocytes were harvested from naı¨ve WT and pik3cg2/2 mice, labelled with CFSE and cultured on anti-CD3
coated tissue culture trays for 72 hours in the presence of anti-CD28 antibodies. Cells were then harvested from culture and divided CD4+ cells
enumerated by flow cytometry. Data shown is from 6 mice per group. (C) Production of IFNc by pik3cg2/2 CD4+ cells is reduced following in vitro TCR
stimulation. Splenocytes were harvested from naı¨ve WT and pik3cg2/2 mice and cultured on anti-CD3 coated tissue culture trays for 72 hours in the
presence of anti-CD28 antibodies. Cells were then harvested from culture and intracellular IFNc detected in live CD4+ cells following 4 hours
activation with PMA/ionomycin in the presence of golgistop and enumerated by flow cytometry. Data shown is from 6 mice per group. All data
shown are mean 6 s.e.m. (*, p,0.05).
doi:10.1371/journal.pone.0045095.g004
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cell migration has been shown to both PI3Kc-dependent [37,38]
and –independent [39,40,41] by various investigators. Taken
together with the results of the present study, it seems likely that
migration into the CNS of encephalitogenic T cells and other
effector leukocytes is reduced during EAE as a result of PI3Kc
deletion or inhibition. Indeed, we also measured reduced CD8+ T
cell activation as a result of PI3Kc deletion and, whilst this may
have limited significance during EAE, these cells have been
strongly implicated in the pathogenesis of MS.
The defects in pik3cg2/2 T cell activation measured in the
present study are likely due to the defects in DC migration
described above, coupled with defective T cell proliferation and
activation following TCR triggering, a process in which conflicting
results have been published with respect to the contribution of
PI3Kc. Perhaps surprisingly, given that TCR signal transduction
leads directly to activation of RTK signalling and PI3Kc is
activated primarily via GPCR stimulation, a role for PI3Kc in T
cell activation both in vitro and in vivo has been clearly
demonstrated previously [13,25]. Following TCR activation,
PI3Kc has been reported to be activated following association
with Gaq/11, ZAP-70 and lck, although whether these interactions
are direct or indirect remains to be determined [25]. However,
Figure 5. Reduced leukocyte infiltration and Th1 and Th17 responses in the CNS of pik3cg2/2 mice during EAE. (A) The number of
CD4+, CD8+, B220+, Ly6G+ and F4/80+ cells in the spinal cord on day 15 post-immunisation was enumerated by flow cytometry (n = 6 mice per group).
(B) Sections of spinal cord from pik3cg2/2 and WT mice at day 15 post-immunization for EAE were prepared and immunofluorescence for CD4
performed (CD4= red, DAPI = blue). Images are representative of those taken from multiple sections. (C) The proportion of Th1 (IFN-c+/IL-172/CD4+
cells) and Th17 (Th17 (IFN-c2/IL-17+/CD4+ cells) cells in the spinal cord was assessed by isolating lymphocytes at days 9 and 15 post-immunization for
EAE and staining for surface CD4 and intracellular cytokines. Representative flow cytometric dot plots of spinal cord CD4+ cells are shown. All data
shown are mean 6 s.e.m. n = 6 mice per group. (*, p,0.05).
doi:10.1371/journal.pone.0045095.g005
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conflicting data suggesting that TCR signalling is PI3Kc in-
dependent also exist. Normal T cell activation was reported in
pik3cg2/2 mice during adjuvant-induced arthritis [42] and
equivalent naı¨ve CD4+ T cell activation was reported between
WT and pik3cg2/2 T cells induced both in vitro and in vivo using
TCR-transgenic mice [38] and in a related study by Berod et al.
[43]. It seems likely that these apparent discrepancies are due to
differences in the T cell activation systems and different read-outs
of activation that have been utilised between these different
studies. Irrespective of this, GPCR ligands have been reported to
influence T cell proliferation, co-stimulation, cytokine production
and survival [44,45,46,47] and it is unlikely that GPCR activation
is necessarily equivalent from one T cell activation system to
another, which tend to vary in the type of TCR-induced
stimulation, costimulatory signals provided and the source and
purity of naı¨ve T cells used. Resulting variations in GPCR
expression or ligand abundance could conceivably influence the
nature of crosstalk between different immuno-receptor signalling
systems engaged in both PI3Kc-dependent and -independent
signals during T cell activation, leading to the diverse outcomes
reported regarding the contribution of PI3Kc in TCR signalling
and PI3Kc-mediated signals may differentially influence pro-
liferation, cytokine production, survival and memory development
of T cells. Importantly, we have measured all of these functional
readouts of T cell activation in the present study, which lends
weight to our conclusion that PI3Kc does indeed play an
important role in T cell activation. In addition, crosstalk and
direct physical interactions between RTKs and GPCRs [48] and
in particular the TCR and GPCRs such as CXCR4 have been
reported [49] and it is likely that PI3Kc makes a substantial
contribution to signalling downstream of these complexes.
Therefore, the diversity in expression of chemokine receptors
and other GPCRs amongst different T cell subsets may also
contribute to the apparently variable contribution made by PI3Kc
in T cell activation, although this remains to be determined in
detail.
This study expands on two recent reports that investigated the
role of PI3Kc in CNS inflammation [43,50]. Consistent with our
results, both reported reduced CNS pathology during experimen-
Figure 6. Increased CD4+ T cell apoptosis in pik3cg2/2 mice during EAE. (A) The proportion of apoptotic (Annexin V+/Propidium iodide+)
cells in the spinal cord was higher in pik3cg2/2mice compared with WT. Representative dot plots gating on CD4+ lymphocytes harvested from spinal
cord taken from mice on day 9 and day 15 of EAE are shown. (B) Increased activation induced cell death in pik3cg2/2 CD4+ T cells. Splenocytes were
harvested from naı¨ve WT and pik3cg2/2 mice and cultured on anti-CD3 coated tissue culture trays for 4 days in the presence of anti-CD28 antibodies.
Every 24 hours from day 1 onward, cells were collected and analysed for the presence of apoptotic (Annexin V+/Propidium iodide+) CD4+ T cells by
flow cytometry. In all cases 5–8 mice were included in each group. Data are mean 6 s.e.m.
doi:10.1371/journal.pone.0045095.g006
Table 2. Effect of AS605240 treatment on EAE.
Treatment % Recovery Mean Cumulative Score Mean Peak Score
Vehicle 0% (0/10) 6.35 (60.85) 1.9560.77
AS605240 60% (6/10)* 3.0 (61.11)* 0.961.17*
Mice were treated with 30 mg/kg AS605240 by oral gavage beginning on the
day of disease onset on a mouse-to-mouse basis. 2 independent experiments,
using a total of 10 mice per group, were performed. Recovery indicates the
percentage of mice that returned to a clinical score of 0 after disease onset.
Peak disease represents the first day an animal reached its highest recorded
clinical disease score and data are shown as mean 6 s.d.
doi:10.1371/journal.pone.0045095.t002
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tal encephalomyelitis in mice lacking p110c. Rodrigues et al.,
reported reduced EAE in pik3cg2/2 mice associated with reduced
expression of the monocyte-attracting chemokines CCL2 and
CCL5 in the CNS, a finding that fits well with our observation that
recruitment of inflammatory cells to the CNS is markedly reduced
in pik3cg2/2 mice. Furthermore, Rodrigues et al., also reported an
increase in apoptotic cells in the CNS of pik3cg2/2 mice using
a TUNEL-based histological approach. Here, we extend their
findings by demonstrating that it is CD4+ T cells that die more
readily by apoptosis at this site, a finding in keeping with a previous
report implicating PI3Kc in memory T cell survival [51] and
similar to our findings using PI3Kd-deficient mice [7]. Berod et al.,
also reported reduced EAE in pik3cg2/2 mice that was associated
with reduced T cell priming in secondary lymphoid tissues.
Furthermore, they also provided evidence that pharmacological
inhibition of PI3Kc with AS605420 reduced EAE, although the
level of disease inhibition reported in that study was substantially
less than that observed in the present study in which 60% of the
animals exhibited complete recovery. This is most likely due to the
alternative routes of administration of the AS605240 inhibitor
employed. In the present study, oral administration of AS606240
was used rather than intraperitoneal injection as performed by
Berod et al. Because it has previously been determined that the
oral route of administration leads to a prolonged in vivo half-life of
this inhibitor when compared with intravenous delivery [18], it is
likely that sustained levels of AS605240 are required for effective
treatment of EAE which is better achieved by oral administration
of AS605240 than by the intraperitoneal route.
At present there are six disease-modifying therapies approved
for use in MS patients (interferon-alpha, interferon-beta, mitox-
antrone, glatiramer acetate, natalizumab and fingolimod) [52,53].
While useful, these therapies are of limited efficacy and can cause
significant adverse side effects. Moreover, none are effective in
treating progressive MS. Therefore more effective and comple-
mentary MS therapies are required. The results of the present
study along with various biochemical and pharmacological studies
indicate that PI3Kc may be a good drug target in MS, due to its
involvement in numerous distinct biochemical processes relevant
to this disease, including regulating leukocyte migration, activation
and survival [10,13,51,54]. It is likely however that PI3Kc only
controls a proportion of each of those processes. A highly selective
PI3Kc inhibitor would therefore be expected to dampen, rather
than completely inhibit, these events. The advantage of targeting
PI3Kc may therefore reside in the fact that mild simultaneous
inhibition of several processes involved in the pathogenesis of
a complex disease such as MS may effectively reduce disease
without significant adverse side effects. Therefore, while PI3Kc
has been shown to make an important contribution in several
models of human inflammatory disease including RA [17,18], SLE
[19], diabetes [20], asthma [21,22] and now MS, whether or not
this enzyme will make a safe and effective drug target in these
human diseases should now be determined.
Previously we demonstrated that the class IA PI3Kd also plays
an important role in EAE [7]. It remains to be determined
whether PI3Kc and PI3Kd play redundant or distinct roles in the
pathogenesis of EAE. However, it is likely that these enzymes play
distinct roles given the clearly divergent modes of activation of
these enzymes (GPCR- vs tyrosine kinase-mediated respectively)
and the disparate immune/inflammatory signalling pathways in
which these enzymes have been implicated (e.g. PI3Kc: neutrophil
migration, neutrophil respiratory burst, mast cell degranulation,
DC migration and T cell activation; PI3Kd: B cell migration, B
cell activation, CD28 signalling, Th17 differentiation) [7,23]. Mice
lacking both PI3Kc and PI3Kd fail to develop peripheral T cells
due to impaired thymocyte development [55,56,57], making
analysis of EAE in mice double deficient in these enzymes highly
problematic. Recently, a new class of PI3K inhibitors that block
both PI3Kc and PI3Kd have been developed [58,59] and follow
up studies will determine whether these are even more potent than
PI3Kc inhibitors alone in treating EAE. Therefore the results of
this study, along with our previous demonstration that PI3Kd also
plays an important role in EAE, suggest that dual PI3K inhibitors
may be particularly effective in MS.
Materials and Methods
Animals and Pharmacological Inhibitors
pik3cg2/2 mice on a C57Bl6 background [10] were obtained
from Professor Shaun Jackson, Monash University, Melbourne,
and bred at the University of Adelaide Animal House. Age and
sex-matched C57BL/6 mice were purchased from The University
of Adelaide Animal House, South Australia or the Australian
Figure 7. Treatment with an orally active PI3Kc inhibitor
inhibits EAE pathogenesis. EAE was induced in WT mice and these
were treated with 30 mg/kg AS605240 or vehicle control by oral gavage
beginning on the day of disease onset on a mouse-to-mouse basis. (A)
Clinical disease scores are plotted as mean 6 s.e.m. from each mouse
from the day of disease onset. Data is pooled from 2 independent
experiments using a total of 10 mice per group. (B) Histology of spinal
cords taken from AS605240 treated and vehicle only treated mice at the
end of the treatment period. As indicated, sections were stained with
haematoxylin and eosin (H+E), luxol fast blue, haematoxylin and eosin
(LFB/H+E). Images are representative of those taken from multiple
sections from 5 mice per group. Arrows indicate lesions or demyeli-
nated areas.
doi:10.1371/journal.pone.0045095.g007
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Research Council and housed at the University of Adelaide
Animal House. AS605240 was purchased from Sigma.
Ethics Statement
All experimental protocols used in this study were approved by
the University of Adelaide Animal Ethics Committee. At all times
the principals of reduce, refine and replace were adhered to and
animal suffering was kept to a minimum.
Induction of EAE
Female wild-type (WT) C57BL/6 or pik3cg2/2 were immunized
subcutaneously in the hind flanks and at the scruff of the neck with
a total of 25 mg Myelin Oligodendrocyte Glycoprotein (MOG)
peptide-35–55 (GL Biochem, China) emulsified in 120 ml Complete
Freund’s Adjuvant (CFA) as previously described [60]. CFA was
prepared by mixing 15% mannide manooleate (Sigma), 85%
mineral oil (Sigma) and 8.33 mg/ml M. tuberculosis (Difco
Laboratories) and grinding extensively using a mortar and pestle.
Two hours prior to immunization, and two days after, the mice
were intravenously injected with 300 ng of pertussis toxin (List
Biological Laboratories Inc., California, USA) in endotoxin-free
PBS. Clinical EAE was evaluated on a scale of 0–5: 0, normal; 0.5,
slight tail weakness; 1, tail weakness 2, hind limb weakness or
a flaccid tail, 2.5 tail paralysis and abnormal gait; 3, hind limb
paralysis; 4, hind and partial fore limb paralysis; 5, moribund.
Collection of Tissues
Mice were euthanized, the right atrium cut and then perfused
through the left ventricle with PBS as previously described [7,60],
before the draining LNs (inguinal and brachial) and the spinal cord
removed. Tissue samples were embedded in Tissue-TekH OCT
embedding medium (Sakra Finetek), frozen and sectioned. In some
instances, cell suspensions were prepared from the draining LNs,
spleens and spinal cords for flow cytometric analysis. Cells were
prepared as previously described [7,60]. For analyses of DCs in
LNs, LNs were minced with a scalpel and then treated with Type
II Collagenase for 30 minutes at 37uC prior to cell suspension
preparation
Immunolabeling Cells for Flow Cytometry
Flow cytometric labeling of cell surface antigens was performed
essentially as previously described [7,60]. In experiments where
intracellular cytokines were detected, cells were activated for 4
hours at 37uC in RPMI containing 20 ng/ml PMA (Sigma), 1 mM
ionomycin (Invitrogen) and GolgistopTM (BD Biosciences). Prior to
addition of antibodies, Fc-receptors were blocked by incubating
cells in PBS/1% BSA/0.04% sodium azide (PBA) containing
200 mg/ml mouse-gamma globulin (Rockland). Following staining
of cell surface antigens, cells were fixed and permeabilized using
a Cytofix/Cytoperm kit (BD Biosciences) according to the
manufacturer’s instructions. The following antibodies were used
in this study (all from BD Biosciences): anti-CD4:PE (553652),
anti-CD4:Alexa Fluor 647 (557681), anti-CD4:PE-Cy7 (552775),
anti-CD11c-PE (553802) and anti-IFN-c-FITC (554411) and anti-
IL-17A-PE (559502), anti-IA-E:biotin (553622), anti-CD69:PE-Cy7
(552879), anti-CD8:Alexa Fluor 647 (557682) anti-CD45R:PE-
Cy5 (553091), anti-Ly6G:FITC (551460), anti-CD49d:PE
(557420), anti-CD62L:PE (553151) and anti-CD62P:FITC
(550866). Anti-mCXCR3 (MAB1685) and anti-mCCR6
(MAB590) antibodies were purchased from R&D Systems. Anti-
F4/80:FITC (11-4801) was purchased from eBiosciences. Anti-
mCCR7 (clone 4B12) was purified from hybridoma supernatant.
Unconjugated primary antibodies were detected by using an anti-
RatIgG:Alexa 647 secondary antibody (Molecular Probes
A21247). In instances where unconjugated primary antibodies
were detected using anti-rat secondary antibodies, an additional
blocking step in 200 mg/ml of rat gamma-globulin (Rockland) was
performed prior to the addition of conjugated rat antibodies.
Biotinylated antibodies were detected using streptavidin-PE-Cy5
purchased from BD Biosciences (554062) In some instances dead
cells were excluded using the Fixable UV live/dead staining kit
(Invitrogen) according to the manufacturer’s instructions
Histology and Immunofluorescence
Spinal cord sectioning and haematoxylin/eosin (H+E) staining
was performed essentially as previously described [7]. In some
instances, luxol fast blue (LFB) staining was performed prior to
H+E staining by fixing sections in ice-cold acetone for 10 minutes
prior to incubating in a 0.1% LFB solution for 2 hours at 60uC.
Slides were then rinsed in 70% ethanol then dH2O, and incubated
in a 0.05% lithium carbonate solution in PBS for 5 seconds before
rinsing in dH2O and then differentiation in 70% ethanol. Rinsing
and differentiation was repeated until the grey matter of the spinal
cord appeared colourless. Slides were then treated for H+E
staining. Immunofluorescence was conducted essentially as pre-
viously described [32]. Briefly, sections were fixed in 100% cold
acetone for 10 minutes and then air-dried and stored overnight at
220uC. All incubations were performed in a humid chamber at
room temperature and all washes were involved three changes
through 1X TBS for 2 minutes per wash. Slides were rehydrated
in 1X TBS, blocked by incubating with 2% normal mouse serum
and 2% normal goat serum in TBS for 30 minutes then washed. A
diluted anti-mouse CD4 monoclonal antibody (BD Biosciences) or
isotype-matched control antibody (BD Biosciences) was added to
appropriate sections and these incubated for 1 hour. Slides were
washed 3X followed by addition of anti-rat Alexa Fluor-647
(Molecular Probes) to the sections, which were then incubated for
45 minutes at room temperature followed by 3 washes. Slides were
then air-dried and coverslips mounted using fluorescence-pre-
serving medium (Vectashield, Vector Laboratories).
In vitro T Cell Activation and Proliferation Assays
T cells harvested from the spleens of 6 week old mice were
activated by culturing on trays pre-coated with anti-CD3 (clone #
2C11) at 10 mg/ml in the presence of 1 mg/ml anti-CD28 at
16106 cells/ml in 200 ml complete RPMI (RPMI 1640 supple-
mented with 10% FCS, 54 pM beta mercaptoethanol, 0.4 mM L-
Glutamine and penicillin/gentamicin). In experiments where cell
division was measured, cells were labeled with CFSE prior to
culture as previously described [32]. Cells were activated for 3
days at 37˚C in 5% CO2. Cells were then harvested and stained for
flow cytometric analysis as described above.
In vivo T Cell Proliferation Assay
BrdU (Sigma, Castle Hill, Australia) was added to drinking
water (0.8 mg/ml) of mice on day 6 post-immunization until day 9
post-immunization. Proliferation was analyzed ex vivo by para-
formaldehyde mediated fixation and permeabilization followed by
FITC-labelled anti-BrdU (Becton Dickinson Immunocytometry,
San Jose, CA) and flow cytometry as previously described [7].
Detection of Apoptotic Cells by Flow Cytometry
This was performed essesntially as previously described [7,61].
In brief, 2.56105 cells were suspended in 100 ml of incubation
buffer (10 mM Hepes/NaOH pH 7.4, 140 nM NaCl, 5 mM
CaCl2) with Annexin-V-Fluos (Roche, 20 ml per 1 ml of in-
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cubation buffer) and Propidium Iodide (Sigma Aldrich, 10 ml per
1 ml of incubation buffer) for 15 minutes before being centrifuged
and re-suspended in incubation buffer for analysis. In some cases
they were first stained with anti-CD4:PE-Cy7 antibodies as
described above. Cells were analyzed within 30 minutes of
labeling.
In vivo Administration of PI3Kc Inhibitor
Mice were treated with 30 mg/kg AS605240 in 100 ml of 0.5%
methylcellulose/0.1% Tween20 in PBS by oral gavage every 12
hours as has been previously described [18].
Statistical Analysis
The two-tailed unpaired Student’s T test was used for all
statistical analyses with the following two exceptions: for EAE
clinical disease analyses, two-way ANOVA analysis was per-
formed; for analysis of the percentage of mice that recovered from
EAE (Table 2), a chi squared test was employed. Statistical tests
were performed using Graphpad Prism 5 software (Graphpad). P
values of ,0.05 were considered significant. In all cases * denotes
P,0.05, ** denotes P,0.01 and *** denotes P,0.001.
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